Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07209046

Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.

This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Adults GLP-1

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The trial begins with a screening to assess eligibility, followed by a 12-week treatment phase during which participants will receive a fixed-dose oral supplementation regimen. During this treatment period, participants will take UltraFlora® Triplebiotic at a fixed dose of 2 capsule per day, administered orally once daily with food. During the 12-week treatment period, participants will be asked to complete questions and track their weight changes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Providing written informed consent
  • Males and females of at least 18 years old
  • Body mass index (BMI) between 25 and 30 (including 25 and 30) (Weight: 25 < BMI < 30)
  • Having undergone treatment with GLP-1 for more than 3 months but for less than 1 year.
  • Having stopped GLP-1 treatment for a maximum of 4 weeks
  • Being willing to maintain stable dietary habits and physical activity levels throughout the trial period
  • Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).

Exclusion criteria

  • Being on GLP-1 treatment
  • Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.
  • Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and/or being immunocompromised.
  • Suffering from any uncontrolled endocrine disorder.
  • Having consumed any probiotic supplements in the 3 months prior to enrollment.
  • Having used any antibiotic treatment in the 3 months prior to enrollment.
  • Having a known allergy to the ingredients in the study product.
  • Being pregnant or lactating (breastfeeding) or trying to become pregnant.
  • Participating in an other clinical trial.
  • Suffering from dementia or inability to take the trial treatment in an appropriate way.
  • Taking UltraFlora® Triplebiotic or any similar product from competitors prior to trial participation

Treatment and study plan

UltraFlora® Triplebiotic

Dietary Supplement

The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of probiotic ( UltraFlora® Triplebiotics, 2 capsules/day) are taken daily with a glass of water.

Placebo

Dietary Supplement

The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of placebo (2 capsule/day) are taken daily with a glass of water.

Primary outcomes

  1. weight measurement

    Time frame: From enrollment to the end of treatment at 12 weeks (90 days)

    Evaluate the impact of UltraFlora Triplebiotic (containing Bifidobacterium Lactis B420 and pasteurized Akkermansia Muciniphila) on weight regain over 3 months after discontinuation of GLP-1.

Secondary outcomes

  1. IBS-SSS (Irritable Bowel Syndrome - Severity Scoring System) questionnaire

    Time frame: From enrollment to the end of treatment at 12 weeks (90 days)

    Evaluate the impact of UltraFlora Triplebiotic containing Bifidobacterium Lactis B420 and pasteurized Akkermansia Muciniphila on weight regain over 3 months after discontinuation of GLP-1. It is a visual analog scale ranging from 0 to 100 that allows the severity of patients' gastrointestinal symptoms to be assessed. The higher the score, the more pain the patient is experiencing.

  2. SVS (Subjective Vitality Scale) questionnaire

    Time frame: From enrollment to the end of treatment at 12 weeks (90 days)

    Evaluate the impact of UltraFlora Triplebiotic containing Bifidobacterium Lactis B420 and pasteurized Akkermansia Muciniphila on vitality using the Subjective Vitality Scales (SVS) questionnaire. This questionnaire assesses a state of well-being and optimal functioning in relation to independence and physical and psychological health. Scores range from 1 (very low vitality) to 7 (optimal vitality).

  3. TFEQ-R18 (Three-Factor Eating Questionnaire - Revised 18 items) Questionnaire

    Time frame: From enrollment to the end of treatment at 12 weeks (90 days)

    Evaluate the impact of UltraFlora Triplebiotic containing Bifidobacterium Lactis B420 and pasteurized Akkermansia Muciniphila on Hunger, Appetite and Cravings using the TFEQ-R18 Questionnaire over the course of 90 days. The TFEQ-R18 is a psychometric questionnaire that assesses eating behaviors and attitudes toward food. There are three dimensions: CR = conscious restraint, UE = uncontrolled eating, EE = emotional eating. High scores in UE or EE indicate an increased risk of overeating, weight gain, or eating disorders. A high score in CR shows a strong desire to restrict intake, but this is sometimes associated with episodes of disinhibition if the restriction fails.

Other outcomes

  1. Assessment of appetite (e.g., number of meals) and food cravings (e.g., snacking or food preferences) in seven questions.

    Time frame: From enrollment to the end of treatment at 12 weeks (90 days)

    How hungry were you today? How full do you feel right now? How many meals ? Did you think about your next meal when you finished your meal? How many craving did you have today? How strong is your desire to eat? How much food do you think you could eat right now?

  2. Side effects experienced when taking the test product or placebo throughout the study (product tolerance)

    Time frame: The proportion of participants at day 14 (T1), day 30 (T2), day 60 (T3), day 90 (T4),

    Expressed any of the following symptoms: headache(s), rash(es), cough, changes in appetite, or other.

  3. patient satisfaction with product use and recommendation

    Time frame: The proportion of participants that at day 90 (T4):

    Evaluate the impact of UltraFlora Triplebiotic containing Bifidobacterium Lactis B420 and pasteurized Akkermansia Muciniphila after 90 days.

    Is satisfied with the intervention ? Would recommend the product ? Would purchase the product ?

Study contacts

Contact information is provided by the study sponsor or research team.

Irfan Qureshi, MD

CONTACT

[email protected]

800-843-9660

Sponsors and collaborators

Lead sponsor

Metagenics, Inc.

Industry

Registry information

Official study title

A Randomized, Double-blind, Double-arm Study Conducted Directly With Consumers Via an App "Baritastic App", Evaluating the Efficacy of a Supplement Containing Bifidobacterium Lactis B420 and Pasteurized Akkermansia Muciniphila (UltraFlora® Triplebiotic) for 3 Months in Adults After Discontinuation of GLP-1 Treatment.

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 6, 2025
Registry last updated
Oct 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.